Evidence map›Paper›PMID 42095068›Full record

ArticleUpsala journal of medical sciences2026

Positron Emission Tomography imaging of tumor necrosis factor in lung injury.

Olivia Wegrzyniak, Huayi Han, Olof Eriksson

Abstract read
In one paragraph

Article in Upsala journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Olivia WegrzyniakScience for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Huayi HanScience for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Olof ErikssonScience for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0000-0002-2515-8790

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Tumor necrosis factor (TNF) is a key pro-inflammatory cytokine involved in various pulmonary diseases, including idiopathic pulmonary fibrosis (IPF), where it contributes to immune cell recruitment, tissue remodeling, and disease progression. Despite the therapeutic potential of TNF-targeting strategies, the lack of non-invasive tools to assess TNF activity in the lungs limits personalized treatment and trial stratification. This study aimed to evaluate the novel Affibody molecule-based positron emission tomography (PET) tracer [ Methods: DOTA-Z Results: DOTA-Z Conclusion: [

Indexed as

Lung InjuryPositron-Emission TomographyTumor Necrosis Factor-alphaAnimalsBleomycinDisease Models, AnimalGallium RadioisotopesHumansInflammationLungMaleRadiopharmaceuticalsRatsRats, Sprague-DawleyTissue DistributionBleomycinGallium-68Gallium RadioisotopesRadiopharmaceuticalsTumor Necrosis Factor-alphainflammationinflammatory diseasesmolecular imagingpositron emitted tomographyTumor necrosis factor

Identifiers

PMID42095068
PMCPMC13142652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.